Raymond James & Associates Sells 20,495 Shares of Repligen Co. (NASDAQ:RGEN)

Raymond James & Associates cut its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 30.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 46,724 shares of the biotechnology company's stock after selling 20,495 shares during the period. Raymond James & Associates owned about 0.08% of Repligen worth $8,401,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Fortis Capital Advisors LLC increased its holdings in Repligen by 32.7% during the first quarter. Fortis Capital Advisors LLC now owns 272 shares of the biotechnology company's stock worth $46,000 after buying an additional 67 shares during the last quarter. Signaturefd LLC increased its holdings in Repligen by 44.1% during the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company's stock worth $45,000 after buying an additional 86 shares during the last quarter. First Horizon Advisors Inc. increased its holdings in Repligen by 14.8% during the third quarter. First Horizon Advisors Inc. now owns 675 shares of the biotechnology company's stock worth $107,000 after buying an additional 87 shares during the last quarter. Daiwa Securities Group Inc. increased its holdings in Repligen by 3.2% during the third quarter. Daiwa Securities Group Inc. now owns 3,200 shares of the biotechnology company's stock worth $509,000 after buying an additional 100 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its holdings in Repligen by 2.5% during the third quarter. Teacher Retirement System of Texas now owns 4,098 shares of the biotechnology company's stock worth $652,000 after buying an additional 101 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Stifel Nicolaus lifted their price objective on shares of Repligen from $165.00 to $207.00 and gave the stock a "buy" rating in a research report on Thursday, February 22nd. JPMorgan Chase & Co. lifted their price objective on shares of Repligen from $170.00 to $210.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 20th. Finally, KeyCorp lifted their price objective on shares of Repligen from $210.00 to $220.00 and gave the stock an "overweight" rating in a research report on Thursday, February 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $196.70.

Insiders Place Their Bets

In other Repligen news, Director Karen A. Dawes sold 1,000 shares of the business's stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the transaction, the director now owns 87,367 shares of the company's stock, valued at $16,892,409.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Karen A. Dawes sold 1,000 shares of the company's stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the transaction, the director now owns 87,367 shares of the company's stock, valued at $16,892,409.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Ralf Kuriyel sold 3,517 shares of the company's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the transaction, the vice president now directly owns 24,260 shares of the company's stock, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,597 shares of company stock valued at $5,039,532. 1.10% of the stock is currently owned by corporate insiders.

Repligen Price Performance

RGEN stock traded up $0.87 during midday trading on Friday, reaching $173.81. The company had a trading volume of 590,003 shares, compared to its average volume of 369,182. The company has a market capitalization of $9.71 billion, a price-to-earnings ratio of 241.41, a price-to-earnings-growth ratio of 5.69 and a beta of 1.02. The stock has a 50 day moving average price of $193.85 and a 200-day moving average price of $172.66. Repligen Co. has a 1-year low of $110.45 and a 1-year high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 7.02 and a quick ratio of 5.75.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts' consensus estimates of $0.33. The business had revenue of $155.74 million during the quarter, compared to the consensus estimate of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. Repligen's revenue for the quarter was down 16.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.68 earnings per share. Equities research analysts expect that Repligen Co. will post 1.46 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.